Short Interest in GeoVax Labs, Inc. (NASDAQ:GOVX) Grows By 341.9%

GeoVax Labs, Inc. (NASDAQ:GOVX) saw a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,330,000 shares, an increase of 341.9% from the October 31st total of 301,000 shares. Based on an average daily volume of 1,900,000 shares, the days-to-cover ratio is currently 0.7 days.

Analysts Set New Price Targets

Several equities analysts recently issued reports on GOVX shares. Noble Financial boosted their target price on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. D. Boral Capital restated a “buy” rating and issued a $18.00 target price on shares of GeoVax Labs in a report on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a report on Friday, November 15th. Finally, Alliance Global Partners initiated coverage on shares of GeoVax Labs in a report on Monday, November 11th. They set a “buy” rating and a $15.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $14.20.

GeoVax Labs Trading Up 0.4 %

GOVX stock traded up $0.01 during trading on Wednesday, reaching $2.71. The stock had a trading volume of 441,786 shares, compared to its average volume of 2,469,405. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18. The company’s 50 day moving average is $2.34 and its two-hundred day moving average is $2.68.

GeoVax Labs (NASDAQ:GOVX) last released its earnings results on Tuesday, November 12th. The company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.38. The company had revenue of $2.79 million for the quarter, compared to the consensus estimate of $1.84 million. During the same period in the prior year, the company earned ($4.80) earnings per share. Research analysts anticipate that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GeoVax Labs stock. Virtu Financial LLC acquired a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned 0.43% of GeoVax Labs at the end of the most recent quarter. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.